Clinical trials
Cholangiocarcinoma Non-resectable clinical trials
Below are recruiting cholangiocarcinoma non-resectable clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05978609RecruitingPhase 2
Testing cadonilimab plus chemotherapy for advanced bile duct cancer
This trial tests a new combination therapy for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. It combines a drug called cadonilimab with standard chemotherapy to see if it works better than chemotherapy alone.
Chengdu, SichuanAges 18–75 - NCT03364530RecruitingPhase 2
Liver artery chemotherapy for non-surgical bile duct cancer
This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.
AmiensAges 18 years+ - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT04556214Recruiting
Liver transplant test for certain bile duct cancers
This trial studies whether a liver transplant can help people with a non-removable type of bile duct cancer in the liver. To be eligible, the cancer must be in the liver only (no spread), and you typically must already have had at least 6 months of treatment before being listed for transplant.
OsloAges 18 years+ - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT06098547Recruiting
Liver transplant for bile duct cancer that can't be removed
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. You must have had at least six months of chemotherapy and your cancer must be stable or smaller before you can be listed for a transplant.
PadovaAges 18–70 - NCT06125769Recruiting
Liver transplant for hard-to-treat bile duct cancer
This trial studies liver transplantation to treat a specific bile duct cancer (perihilar cholangiocarcinoma) that cannot be removed by surgery. It aims to see if a transplant can help when standard chemotherapy has kept the cancer stable.
Padova, PADOVAAges 18–70 - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06850753Recruiting
En bloc removal of liver and pancreas with transplant for bile duct cancer
This trial tests a new surgical approach that removes the liver, pancreas, and bile duct all at once (and then gives a liver transplant) for people with a type of bile duct cancer that cannot be removed with standard surgery. It may help people whose cancer is limited to the liver area and who have not responded to other treatments.
OsloAges 18–70 - NCT06671418Enrolling by invitationPhase 3
Stenting vs drainage for blocked bile ducts from cancer
This study compares two ways to open blocked bile ducts near the liver due to cancer that cannot be removed. One method uses a stent placed through the skin (percutaneous stenting), and the other uses a tube placed through a scope (endoscopic drainage). The goal is to see which approach works better for relieving jaundice and improving quality of life.
RotterdamAges Any age - NCT05551299RecruitingPhase 4
Non-surgical treatment for bile duct cancer using heat or light
This trial tests whether treating hilar bile duct cancer with either radiofrequency ablation (heat) or photodynamic therapy (light-activated medicine) can help patients when surgery isn’t an option. It aims to treat the tumor directly without planned surgery soon.
AachenAges 18 years+ - NCT07364305RecruitingPhase 2
Hepatic artery infusion + immunotherapy for advanced bile duct cancer
This trial tests combining a liver-directed chemotherapy infusion (HAIC) with immunotherapy to shrink advanced bile duct cancer that cannot be removed surgically. The goal is to slow tumor growth and improve survival.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05844046RecruitingPhase 2
Triple drug treatment for advanced liver cancer that can’t be removed
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
MunichAges 18 years+ - NCT06375486RecruitingPhase 2
Ivonescimab and HAIC for Unresectable Liver Cancer
This trial tests a combination of a targeted immunotherapy drug (ivonescimab) and a liver-directed chemotherapy infusion (HAIC) for people with liver cancer that cannot be removed by surgery. It may be an option if you have not had prior systemic treatment for your liver cancer.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Cholangiocarcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangiocarcinoma non-resectable?
- Yes. Clin2 currently lists 16 recruiting cholangiocarcinoma non-resectable studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangiocarcinoma non-resectable trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangiocarcinoma non-resectable trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.